首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 分子標靶治療學 > 附帶診斷:課題、機會、未來動向
產業/市場分類
生物科技 (1470)
分子標靶治療學 (51)
生技設備 (321)
生物材料 (55)
生物標記 (157)
以基因為基之藥物開發 (201)
再生醫學 (120)
抗體和免疫 (187)
個人化醫學 (54)
基因治療學和RNAi (101)
市場調查報告書

附帶診斷:課題、機會、未來動向

The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends

出版商 Decision Resources, Inc.
出版日期 2008年06月 商品編碼 68537
內容資訊 英文 35 Pages
價格
US $ 2250 PDF by E-mail (Global License)


附帶診斷:課題、機會、未來動向 是由出版商Decision Resources, Inc.在2008年06月所出版的。 這份英文市場調查報告書包含35 Pages 價格從美金2250起跳。

簡介

此報告書的內容包括投入附帶診斷市場的企業之簡介與相同市場的課題、各治療領域的動向、未來的前景等。報告書之內容摘要如下所示。

摘要

為何是附帶診斷呢

RxDx市場動向

  • 市場中的附帶診斷實驗
  • 附帶診斷目前的主要企業
    • Abbott Diagnostics
    • Clinical Data
    • Dako
    • Genzyme Genetics

決定共同開發附帶診斷的主要因素

  • 為何企業要共同開發標的治療與附帶診斷呢
  • 為何製藥公司需要確立並行計畫呢

附帶診斷的經濟學

附帶診斷的開發課題

  • 技術性課題
  • 對於診斷實驗的規定
    • 美國
    • 歐洲
  • 藥劑歸類
  • 償還問題與課題
    • 個人醫療
    • 負擔保險人員
    • 償還政策
  • 規定問題
  • 未來的前景與償還的可能性

各治療領域的新興附帶診斷

  • 傳染病
  • 循環器官
  • 糖尿病
  • 呼吸器官疾病

附帶診斷的市場機會

未來前景

圖表

目錄

Abstract

Introduction

Diagnostics can be used to identify subgroups of patients who may or may not benefi t from a companion drug, who may have adverse reactions to that drug, or who may require different doses of that drug because of their particular metabolic activity. The concept of companion diagnostics as an integral component of personalized medicine-RxDx-is an emerging and critical paradigm for drug development and use. What is driving that paradigm?

Get the Answers You Need to Shape Your Strategy

  • More than a dozen companion diagnostic tests are approved for use in the United States and guide the prescription of products in oncology, cardiovascular disease, and infectious diseases. What are the most successful RxDx products, and will their success encourage further development? Why are companies reluctant to abandon the blockbuster model in favor of personalized medicine?
  • Personalized medicine continues to be heavily debated within the industry, and future growth depends on more attention from all stakeholders. What is each stakeholder' s role in RxDx collaborations, and how can these collaborations drive development? What does each player have to offer the others to encourage development and reconcile debate? Why are parallel development programs critical?
  • Reimbursement issues are an important factor that will determine whether the pharmaceutical industry is willing to invest in RxDx, but current reimbursement policies can be discouraging. What evidence must companies provide to third-party payers to demonstrate value and ensure reimbursement? What are the policies and issues surrounding reimbursement? With few RxDx products on the market and even fewer reimbursed, how can R&D costs ever be recovered?

Scope

  • Key players: Abbott Diagnostics, Clinical Data, Dako, Genzyme Genetics.
  • Challenges in RxDx development: technological challenges, regulation, drug labeling, reimbursement.
  • Emerging companion diagnostics by therapeutic area: oncology, infectious diseases, cardiology, central nervous system (CNS) indications, diabetes, respiratory therapeutics; profi les of select companies working in RxDx.
  • Outlook: future of companion diagnostics development, company buy-in, the affect of personalized medicine on prescription sales, the role of regulatory agencies.

Table of Contents

  • Executive Summary
    • Strategic Considerations
    • Stakeholder Implications
  • Why Companion Diagnostics?
  • RxDx Market Status
    • Companion Diagnostic Tests on the Market
    • Key Current Players in Companion Diagnostics
      • Abbott Diagnostics
      • Clinical Data
      • Dako
      • Genzyme Genetics
  • Determinants of Codeveloping Companion Diagnostics
    • Why Should Companies Codevelop Targeted Therapies and Companion Diagnostics?
    • Why Do Pharmaceutical Companies Need to Establish Parallel Programs?
  • Economics of Producing Companion Diagnostics
  • Challenges in Developing Companion Diagnostics
    • Technological Challenges
    • Regulation of Diagnostic Tests
      • United States
      • Europe
    • Drug Labeling
    • Reimbursement Issues and Challenges
      • Personalized Medicines
      • Payers
      • Reimbursement Policies
    • Coding Issues
    • Determining Prospects and Potential for Reimbursement
  • Emerging Companion Diagnostics by Therapeutic Area
    • Oncology
      • Biodesix
      • bioMérieux
      • Celera
      • GE Healthcare
      • Monogram Biosciences
      • Roche
      • Source MDx
    • Infectious Diseases
      • Abbott
      • Monogram Biosciences
      • Roche
      • Visible Genetics
    • Cardiology
      • PGxHealth
      • LabCorp
      • Nanosphere
    • Central Nervous System Indications
      • Adlyfe
      • Curidium
      • Clinical Data
      • ExonHit Therapeutics
      • Vanda Pharmaceuticals
    • Diabetes
      • Perlegen
      • Tethys Bioscience
    • Respiratory Therapeutics
  • Market Opportunities for Companion Diagnostics
    • Getting the "Buy-In" from Companies
    • Expanding Therapeutic Area Coverage
  • Outlook
    • Will We See More Companion Diagnostics on the Market?
    • Will RxDx Negatively Affect Rx Sales?
    • Will More Companies Join the Personalized Medicine Bandwagon?
    • Will There Be More Codevelopment of Therapeutics and Diagnostics?

Sidebars

  • Common Defi nitions of Terms Associated with Companion Diagnostics
  • Regulation of Diagnostic Tests in the United States
  • Third-Party Payers Infl uencing Reimbursement for Diagnostic Tests
  • Case Study: An RxDx Partnership Informing HIV Treatment

Tables

  • 1. Select FDA-Approved Companion Diagnostic Tests and Associated Therapeutics
  • 2. Collaborations of Leading Companion Diagnostics Developers, 2007-2008
  • 3. Select Companion Diagnostic Tests for Warfarin Dosing
  • 4. Recent Key Collaborations for Companion Diagnostic Development
  • 5. Advantages and Disadvantages of Establishing a Drug and Diagnostic Codevelopment Program
  • 6. Comparison of the Pharma and Diagnostics Industries Business Models

Figures

  • 1. RxDx Codevelopment Process
  • 2. Potential Biomarkers to Guide Treatment with AstraZeneca' s Iressa (Gefi tinib)
  • 3. Impact of Biomarkers on Therapeutic Development and Prescription
  • 4. Benefi t of Companion Diagnostics in the Characterization and Validation of Targeted Therapeutics
Back to Top